Capromab_pendetide

Indium (<sup>111</sup>In) capromab pendetide

Indium (111In) capromab pendetide

Add article description

Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single-photon emission computed tomography (SPECT).[1]

Quick Facts Monoclonal antibody, Type ...

Early trials with yttrium (90Y) capromab pendetide were also conducted.[3]

References

  1. [1]
    Manyak MJ (February 2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy. 8 (2): 175–81. doi:10.1586/14737140.8.2.175. PMID 18279057. S2CID 30587577.
  2. [2]
    WHO Drug Information
  3. [3]
    Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD (April 1999). "A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy". Cancer Biotherapy & Radiopharmaceuticals. 14 (2): 99–111. doi:10.1089/cbr.1999.14.99. PMID 10850293.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Stub icon

This nuclear medicine article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Capromab_pendetide, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.